BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 01, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Perifosine: Updated Phase II data

Updated data from a double-blind, placebo-controlled, U.S. Phase II trial in 35 evaluable patients showed that 50 mg daily perifosine plus 825 mg/m 2 twice-daily Xeloda capecitabine met the primary endpoint of significantly improving median TTP vs. Xeloda alone (28 vs. 11 weeks, p=0.0012). ORR for the combination was 20% (1 complete response (CR) and 3 partial responses (PRs) vs....

Read the full 287 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >